Blood group B can be a predictor of the EGFR mutations in patients with lung adenocarcinoma

The relationship between ABO blood and EGFR mutations in lung adenocarcinoma is still unclear. The purpose of this study was to evaluate the association between ABO blood and EGFR mutations percentage in patients with lung adenocarcinoma. Subject and method: A cross-sectional descriptive study, 276 lung adenocarcinoma patients were tested for EGFR mutations and ABO blood from January 2020 to April 2023.